Biosimulation Market Size To Reach $14.8 Billion By 2033

May 2026 | Report Format: Electronic (PDF)

Biosimulation Market Growth & Trends

The global biosimulation market size is expected to reach USD 14.8 billion by 2033, registering a CAGR of 17.3% from 2026 to 2033, according to a new report by Grand View Research, Inc. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

key Request a free sample copy or view the report summary: Biosimulation Market Report

Biosimulation Market Report Highlights

Software dominated the market, with a revenue share of 59.4% in 2025. This can be attributed to the availability of application-specific software catering to specific research and development requirements.
The drug development segment held the largest market share of 55.4% in 2025, driven by the increasing number of drug development processes.
Oncology held the largest revenue share in 2025. In oncology, biosimulation is crucial in understanding tumor dynamics, treatment responses, and patient-specific factors influencing cancer outcomes.
Cloud-based deployment model dominated the market and held the largest revenue share of over 43.0% in 2025 and is expected to grow at the fastest CAGR during the forecast period.
License-based model held the largest revenue share in 2025. The advantage of this model is that it provides users with access to sophisticated tools without the need for substantial investments in infrastructure or development.
Life science companies accounted for the largest revenue share in 2025. These companies are increasingly adopting biosimulation software as a critical tool in drug development and research.

Biosimulation Market Segmentation

Grand View Research has segmented the global biosimulation market report based on product, application, therapeutic area, deployment model, pricing model, end use, and region:

Biosimulation Product Outlook (Revenue, USD Million, 2021 - 2033)

Software
- Molecular Modeling & Simulation Software
  - Docking, molecular dynamics, QSAR
    - Small Molecules
    - Biologics
  - In-silico ADME (ChemAxon-type tools)
    - Large Pharma (Top ~30)
    - Mid Pharma (~30–300)
    - Emerging / Long-tail Pharma & Biotech
  - Physicochemical property prediction (logP, pKa, solubility, permeability)
- Clinical Trial Design Software
  - Clinical trial simulation
  - Adaptive design
  - Virtual patients
  - Dose optimization
  - MIDD-linked applications
- PK/PD Modeling and Simulation Software
  - Software
    - Compartmental modeling
    - Population PK/PD (Pop PK/PD)
    - Non-compartmental analysis (NCA)
    - Dose-response, bioequivalence
  - Customer
    - Large Pharma (Top ~30)
    - Mid Pharma (~30–300)
    - Emerging / Long-tail Pharma & Biotech
- Pbpk Modeling and Simulation Software
  - ADME (mechanistic)
  - DDI modeling
  - FIH dose prediction
  - Special populations
- Toxicity Prediction Software
  - Hepatotoxicity, cardiotoxicity, genotoxicity
  - QSAR, mechanistic, AI/ML models
  - ADME-linked toxicity
- QSP / Systems Biology Software
  - Software
    - Mechanistic disease modeling
    - Multi-scale simulation
    - Integration with PBPK
  - Customer
    - Large Pharma (Top ~30)
    - Mid Pharma (~30–300)
    - Emerging / Long-tail Pharma & Biotech
- Other Software
  - AI-driven platforms
  - RWD-integrated tools
Services
- Contract Services
  - Services
    - PK/PD services
      - Pop PK/PD
      - NCA
      - Compartmental
  - PBPK services
    - ADME
    - DDI
    - Special populations
  - Customer
    - Large Pharma (Top ~30)
    - Mid Pharma (~30–300)
    - Emerging / Long-tail Pharma & Biotech
- Consulting
  - Large Pharma (Top ~30)
  - Mid Pharma (~30–300)
  - Emerging / Long-tail Pharma & Biotech
- Implementation, Training & Support
  - Service
    - Deployment
    - Integration
    - Training
  - Customer
    - Large Pharma (Top ~30)
    - Mid Pharma (~30–300)
    - Emerging / Long-tail Pharma & Biotech

Biosimulation Application Outlook (Revenue, USD Million, 2021 - 2033)

Drug Discovery & Development
Disease Modeling
Other (Precision Medicine, Toxicology, etc., etc.)

Biosimulation Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

Oncology
Cardiovascular Disease
Infectious Disease
Neurological Disorders
Others

Biosimulation Deployment Model Outlook (Revenue, USD Million, 2021 - 2033)

Cloud-based
On-premise
Hybrid Model

Biosimulation Pricing Model Outlook (Revenue, USD Million, 2021 - 2033)

License-based Model
Subscription-based Model
Service-based Model
Pay Per Use Model

Biosimulation End Use Outlook (Revenue, USD Million, 2021 - 2033)

Life Sciences Companies
- Pharmaceutical Companies
- Biopharma Companies
- Medical Device Companies
- CROs/CDMOs
Academic Research Institutions
Others (Regulatory Authorities, etc.)